Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Novel Modeling Methods for Genomic Data Analysis & Evolutionary Systems Biology to Design Dosing Regimens to Minimize Resistance

Reporter: Aviva Lev-Ari, PhD, RN

Dana-Farber’s Franziska Michor to Present Novel Modeling Methods for Genomic Data Analysis

As part of Discovery on Target’s new Quantitative Systems Pharmacology conference, Dr. Franziska Michor, will provide her team’s experiences in employing state-of the-art modeling methods to address treatment response and the evolution of resistance. The event will be held September 23-24 in Boston and will bring together experts in QSP and the researchers interested in using this methodology.

Featured Presentation: Applying Evolutionary Systems Biology to Design Dosing Regimens to Minimize Resistance

Franziska Michor, Ph.D., Professor, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute,Department of Biostatistics, Harvard School of Public Health

 

Final Agenda

APPLICATIONS OF QSP TO DRUG DISCOVERY AND DEVELOPMENT

Right Target, Right Dose, Right Trial with Limited Animal Use: QSP Doubles the 3R Benefits
Valeriu Damian-Iordcahe, Ph.D., Head, Modelling and Translational Biology, GSK

The QSP Extensibility Concept: A Physiology-Based Multi-Scale Model as a Platform to Address Wide-Ranging Clinical Questions
Mark C. Peterson, Ph.D., Director, Global Pharmacometrics, GIPB Clinical Pharmacology, Pfizer, Inc.

Creating and Performing Research with PhysioPD™ Research Platforms: Overview and Case Study

Ananth Kadambi, Ph.D., Senior Vice President, PhysioPD™, Rosa & Co.

Diverse Application with a Common Underlying Workflow
Saroja Ramanujan, Ph.D., Senior Scientist, Group Lead, Translational & Systems Pharmacology, Genentech

Building Translational Quantitative Pharmacology: The Merck Experience
Prajakti Kothare, Ph.D., Scientific Lead, Early Phase Quantitative Pharmacology & Pharmacometrics, Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck

INTERACTIVE BREAKOUT DISCUSSIONS

Partnerships between Academia, Government and Industry to Implement QSP as A New Paradigm for Drug Discovery

Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute & Allegheny Foundation, Professor of Computational and Systems Biology, University of Pittsburgh

Preclinical-to-Clinical Translation in Oncology: Principles and Best Practices

Arijit Chakravarty, Ph.D., Director, Modeling and Simulation (DMPK), Takeda Pharmaceuticals International Co.

SYSTEMS DISEASE MODELS

A Quantitative Systems Pharmacology (QSP) Framework for Oncology Translational and Early Clinical Development
Arijit Chakravarty, Ph.D., Director, Modeling and Simulation (DMPK), Takeda Pharmaceuticals International Co.

Applying Evolutionary Systems Biology To Design Dosing Regimens To Minimize Resistance
Franziska Michor, Ph.D., Professor, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Department of Biostatistics, Harvard School of Public Health

Development and Application of the Coagulation Systems Model
Fei Hua, Ph.D., Clinical Pharmacology Lead, PharmaTx Clinical Research & Development, Pfizer, Inc.

Applications of Quantitative Systems Pharmacology (QSP) in Crohn’s Disease Drug Discovery and Development
Oliver Ghobrial, Ph.D., Senior Research Scientist III, Translational Modeling and Simulation, AbbVie

Adaptive Resistance and Fractional Response of Cancer Cells to Therapy
Mohammad Fallahi-Sichani, Ph.D., Merck Fellow of the Life Sciences Research Foundation, Department of Systems Biology, Harvard Medical School

QSP FOR BIOMARKERS IDENTIFICATION AND DEVELOPMENT

Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery in Academia

Lansing Taylor, Ph.D., Director, University of Pittsburgh Drug Discovery Institute & Allegheny Foundation, Professor of Computational and Systems Biology, University of Pittsburgh

Systems Pharmacology Insights for Patient Selection for Liposomal Anti-Cancer Therapy: From Idea to Clinical Evaluation
Bart Hendriks, Ph.D., Director, Research & Development, Merrimack Pharmaceuticals

TECHNOLOGIES FOR QUANTITATIVE PHARMACOLOGY

Engineering Targeted Growth Factors to Repair Heart Tissue Following Ischemic Injury
Matthew Onsum, Ph.D., President and CEO, Silver Creek Pharmaceuticals

Kriging – An Emerging Technology with the Potential of Improving the Precision of in silico Predictions and Eliminating the Need for Creating Local Models
Istvan Enyedy, Ph.D., Senior Scientist, Chemistry and Molecular Therapeutics, Biogen

A Massively Orthogonal Pharmacology Search Engine: Can All of Our Models and Data Be “GoogledTM”?
Douglas Selinger, Ph.D., Manager, Bioinformatics, Preclinical Safety, Novartis Institutes for BioMedical Research

Also Available at Discovery on Target:

Short Course: Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach (Separate Registration Required)

SOURCE

From: “Quantitative Systems Pharmacology” <jaimeh@healthtech.com>

Date: July 1, 2015 at 9:20:00 AM EDT

To: avivalev-ari@alum.berkeley.edu

Subject: Dana-Farber’s Franziska Michor Presents Novel Modeling for Genomic Data